For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, uniQure N.V’s stock clocked out at $12.23, down -2.24% from its previous closing price of $12.51. In other words, the price has decreased by -$2.24 from its previous closing price. On the day, 0.66 million shares were traded.
Ratios:
To gain a deeper understanding of QURE’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.74 and its Current Ratio is at 9.74.
Goldman Downgraded its Buy to Neutral on February 29, 2024, while the target price for the stock was maintained at $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 04 ’25 when Kapusta Matthew C sold 28,341 shares for $10.29 per share. The transaction valued at 291,629 led to the insider holds 651,454 shares of the business.
Abi-Saab Walid sold 1,350 shares of QURE for $13,891 on Mar 04 ’25. The Chief Medical Officer now owns 151,903 shares after completing the transaction at $10.29 per share. On Mar 04 ’25, another insider, KLEMT CHRISTIAN, who serves as the Chief Financial Officer of the company, sold 10,438 shares for $10.29 each. As a result, the insider received 107,407 and left with 217,730 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 24.39.
Stock Price History:
Over the past 52 weeks, QURE has reached a high of $19.18, while it has fallen to a 52-week low of $3.73. The 50-Day Moving Average of the stock is -16.49%, while the 200-Day Moving Average is calculated to be 41.11%.
Shares Statistics:
A total of 48.99M shares are outstanding, with a floating share count of 47.24M. Insiders hold about 12.26% of the company’s shares, while institutions hold 75.95% stake in the company.
